Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
CrowdStrike Holdings Inc
CRWD
Industrials
Technology
Conglomerates
Information Technology Services
CrowdStrike Holdings, Inc. is a global cybersecurity company that provides cloud-delivered protection of endpoints, cloud workloads, identity and data. The Company’s Falcon platform is designed for cybersecurity consolidation, purpose-built to stop breaches. The platforms collect and integrates data from across the enterprise, including endpoints, cloud workloads, identities, and third-party...
sources. The Company's Falcon platform leverages a single lightweight-agent architecture with integrated cloud modules spanning multiple security markets, including corporate workload security, managed security services, security and vulnerability management, information technology (IT) operations management, threat intelligence services, identity protection and log management. The Company offers 27 cloud modules on its Falcon platform via a software-as-a-service (SaaS) subscription-based model that spans multiple large markets, including corporate endpoint and cloud workload security, and more.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:CRWD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
Next
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 05, 2024 2:00pm
These Analysts Revise Their Forecasts On CrowdStrike After U
JUST IN: $CRWD These Analysts Revise Their Forecasts On CrowdStrike After Upbeat Results | BenzingaCrowdStrike Holdings Inc (NASDAQ:CRWD) reported better-than-expected financial results for the first
...more
(621)
•••
jboom70
X
View Profile
View Bullboard History
Post by
jboom70
on May 30, 2024 6:15pm
Zs
killed on earnings. The turn around tomorrow will be violent.
Access North American AND Australian listed and Pre-IPO opportunities – here!
posted Dec 27, 2024 9:00am by
Stockhouse Publishing Ltd.
-
|
For the first time on Stockhouse, Canadian investors can access ASX-listed opportunities through our partnership with HotCopper in Australia, opening doors to high-potential investments at the click of a button. Learn more here… ...read more
(0)
•••
DianaScanlan
X
View Profile
View Bullboard History
Post by
DianaScanlan
on Apr 13, 2023 4:04am
Kevin Harrington Discusses FSD Pharma
I believe this new product will aid society in reducing the
...more
(0)
•••
Peng26
X
View Profile
View Bullboard History
Post by
Peng26
on Apr 13, 2023 3:35am
FSD Pharma Inc is about to launch this breakthrough product
(2)
•••
jw1trader
X
View Profile
View Bullboard History
Post by
jw1trader
on Aug 31, 2022 2:24pm
41% below where they were in November
As cyberattacks throughout the world have increased since Russia invaded Ukraine at the end of February of this year, the Austin, Texas-based company has gained a lot of media attention for
...more
(0)
•••
DianaScanlan
X
View Profile
View Bullboard History
Post by
DianaScanlan
on Jul 15, 2022 9:39pm
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent
(0)
•••
DianaScanlan
X
View Profile
View Bullboard History
Post by
DianaScanlan
on Jun 03, 2022 5:23am
FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance
FSD Pharma ready to proceed with Phase 2 clinical trial of
...more
(0)
•••
DianaScanlan
X
View Profile
View Bullboard History
Post by
DianaScanlan
on Jun 02, 2022 12:33am
FSD Pharma Files Investigational New Drug Application “IND”
(0)
•••
DianaScanlan
X
View Profile
View Bullboard History
Post by
DianaScanlan
on May 11, 2022 1:45am
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
(0)
•••
DianaScanlan
X
View Profile
View Bullboard History
Post by
DianaScanlan
on May 01, 2022 11:50pm
Lucid-MS for Multiple Sclerosis Treatment
(0)
•••
DianaScanlan
X
View Profile
View Bullboard History
Post by
DianaScanlan
on Apr 24, 2022 1:56am
"Julia Levy Award" Recipient David Allan and Dr. John McGraw
(0)
•••
DianaScanlan
X
View Profile
View Bullboard History
Post by
DianaScanlan
on Apr 18, 2022 2:34am
FSD Pharma Inc: Lucid MS Video
FSD Pharma is delighted to announce pre-clinical findings
...more
(0)
•••
DianaScanlan
X
View Profile
View Bullboard History
Post by
DianaScanlan
on Apr 09, 2022 12:29pm
FSD: Cancellation of Certain Shares Issued to Former CEO
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA
...more
(0)
•••
DianaScanlan
X
View Profile
View Bullboard History
Post by
DianaScanlan
on Apr 07, 2022 12:40pm
FSD Pharma Issues Corporate Updates
FSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to
...more
Prev
...
41
42
43
44
45
46
47
48
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Growth Rocket 2025 – Why dynaCERT is in the Spotlight
A potential breakthrough in spinal cord and optic nerve injury treatment
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product
Debt-Free Cannabis Company Set for Next Stage of Growth